» Articles » PMID: 19884815

Increased Urinary Angiotensinogen is Precedent to Increased Urinary Albumin in Patients with Type 1 Diabetes

Overview
Journal Am J Med Sci
Publisher Elsevier
Specialty General Medicine
Date 2009 Nov 4
PMID 19884815
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We previously reported that kidney and urinary angiotensinogen levels were significantly increased before the development of diabetic nephropathy in diabetic rats. To address this system in humans, we have developed an enzyme-linked immunosorbent assay for human angiotensinogen and reported that urinary excretion of angiotensinogen levels is enhanced in patients with chronic kidney disease, including patients with type 2 diabetes. On the basis of these findings, this study was performed to demonstrate that urinary angiotensinogen levels increased before the onset of microalbuminuria and that urinary angiotensinogen can be an early biomarker of intrarenal renin-angiotensin system status in normoalbuminuric patients with type 1 diabetes compared with age- and sex-matched control subjects.

Methods: The study included 28 patients with type 1 diabetes and 21 control subjects. No subject received renin-angiotensin system blockades. Random spot urine samples as well as blood samples were obtained and analyzed.

Results: Urinary albumin:creatinine ratio or urinary protein:creatinine ratio did not increase in patients compared with control subjects, suggesting that these patients were in their premicroalbuminuric phase of diabetic nephropathy. However, the urinary angiotensinogen:creatinine ratio was significantly higher in patients than in control subjects (12.1 +/- 3.2 microg/g versus 4.2 +/- 0.7 microg/g). Importantly, an increase in plasma angiotensinogen levels was not observed (26.3 +/- 1.3 microg/mL versus 29.5 +/- 3.3 microg/mL).

Conclusions: Thus, in patients, an increase in urinary angiotensinogen levels is observed, and this increase is precedent to an increase in urinary albumin levels, suggesting that urinary angiotensinogen may function as an early marker of diabetic nephropathy.

Citing Articles

Comparative diagnostic utility of different urinary biomarkers during pre-albuminuric stages of non-hypertensive type 2 diabetic nephropathy.

Mahapatra H, Kulshreshtha B, Goyal P, Chitkara A, Kumari A, Arora A Indian J Med Res. 2022; 156(1):46-55.

PMID: 36510897 PMC: 9903381. DOI: 10.4103/ijmr.IJMR_455_21.


Biomarkers for early diagnosis of diabetic kidney disease: still a long way to go.

Kumar V, Kohli H Indian J Med Res. 2022; 156(1):14-16.

PMID: 36510893 PMC: 9903386. DOI: 10.4103/ijmr.ijmr_1094_22.


Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy.

Navarro J, Sanchez A, Ba Aqeel S, Ye M, Rehman M, Wysocki J Kidney Int Rep. 2022; 7(12):2657-2667.

PMID: 36506234 PMC: 9727532. DOI: 10.1016/j.ekir.2022.09.010.


Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Lin H, Geurts F, Hassler L, Batlle D, Mirabito Colafella K, Denton K Pharmacol Rev. 2022; 74(3):462-505.

PMID: 35710133 PMC: 9553117. DOI: 10.1124/pharmrev.120.000236.


Angiotensinogen and Risk of Stroke Events in Patients with Type 2 Diabetes Mellitus.

Liu T, Liu W Diabetes Metab Syndr Obes. 2022; 15:419-425.

PMID: 35177918 PMC: 8846557. DOI: 10.2147/DMSO.S335746.


References
1.
Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

2.
Lantelme P, Rohrwasser A, Gociman B, Hillas E, Cheng T, Petty G . Effects of dietary sodium and genetic background on angiotensinogen and Renin in mouse. Hypertension. 2002; 39(5):1007-14. DOI: 10.1161/01.hyp.0000016177.20565.a0. View

3.
Kobori H, Nangaku M, Navar L, Nishiyama A . The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59(3):251-87. DOI: 10.1124/pr.59.3.3. View

4.
Miyata K, Ohashi N, Suzaki Y, Katsurada A, Kobori H . Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2008; 35(8):922-7. PMC: 2575127. DOI: 10.1111/j.1440-1681.2008.04938.x. View

5.
Singh R, Singh A, Leehey D . A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol. 2005; 288(6):F1183-90. DOI: 10.1152/ajprenal.00159.2003. View